Iovance Biotherapeutics Inc (NAS:IOVA)
$ 9.32 -0.08 (-0.85%) Market Cap: 2.84 Bil Enterprise Value: 2.52 Bil PE Ratio: 0 PB Ratio: 3.67 GF Score: 39/100

Iovance Biotherapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 03:50PM GMT
Release Date Price: $52.03 (+2.77%)
Unidentified Analyst

Good morning, everyone. My name is [Antoine Natale], and I'm a member of the JPMorgan health care investment banking team. Thank you all for joining us today. It is my pleasure to introduce Maria Fardis, President and CEO of Iovance.

As a reminder, you may submit questions through the ask-a-question feature, which is listed under the presentation on the website. We would advise you to submit your questions live during the session, and they will be answered at the end.

Maria, back to you.

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Thank you, Antoine. Good morning. I will be speaking about tumor-infiltrating100 lymphocyte cell therapy for treatment of solid tumors.

I'm moving to Slide 2, where our forward-looking statements is noted. We are a public company, so I draw your attention to those statements.

On Slide 3, we're showing you what is the goal for the company. As I noted, this is a cell therapy company for treatment of solid tumors. We aim to bring TIL therapy into

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot